HK Stock Market Move | BIOCYTOGEN-B (02315) rose more than 7% during trading hours, and the company's A shares will be available for subscription on November 28. The company achieved a turnaround from losses to profits in the third quarter.

BIOCYTOGEN-B (02315) rose more than 7% during the trading session, and as of the time of writing, it had increased by 4.87% to HK$31.9, with a trading volume of HK$113.572 million. On the news front, on November 20th, Baiosesto disclosed its IPO prospectus, planning to list on the Shanghai Stock Exchange's Science and Technology Innovation Board. The preliminary inquiry date is November 25, 2025, and the subscription date is November 28, 2025. It is worth noting that the IPO prospectus for A-shares includes comprehensive financial information for the nine months ending on September 30, 2025. For the first three quarters of 2025, the company's operating income was 941 million yuan, a year-on-year increase of 59.5%; net profit attributable to shareholders was 114 million yuan, reversing the previous year's loss; net cash flow from operating activities was 263 million yuan, a year-on-year increase of 162.2%; and research and development expenses amounted to 313 million yuan, a year-on-year increase of 30.6%.